Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Hepatitis

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 54 articles:
HTML format



Single Articles


    November 2023
  1. WANG X, Liu H, Wang P, Wang Y, et al
    A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepatitis.
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002661.
    PubMed     Abstract available


  2. UZEL A, Ebik B, Bucaktepe GE, Yolacan R, et al
    Do oral antiviral drugs used in the treatment of chronic hepatitis B cause erectile dysfunction?
    Eur J Gastroenterol Hepatol. 2023 Nov 7. doi: 10.1097/MEG.0000000000002672.
    PubMed     Abstract available


  3. TSAI PS, Cheng YM, Wang CC, Kao JH, et al
    The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Eur J Gastroenterol Hepatol. 2023;35:1278-1283.
    PubMed     Abstract available


    October 2023
  4. OZDEN I, Kinaci E, Ocak I, Colak M, et al
    Successful results of early nucleos(t)ide analogue treatment for liver transplantation candidates with severe acute hepatitis B infection.
    Eur J Gastroenterol Hepatol. 2023 Oct 6. doi: 10.1097/MEG.0000000000002655.
    PubMed     Abstract available


    September 2023
  5. LIAO Y, Liang T, He Y, Mo S, et al
    Correlation between ABO blood group and prognosis of hepatectomy for hepatitis B virus-associated hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2023;35:1012-1022.
    PubMed     Abstract available


  6. JENSEN AH, Ytting H, Winther-Sorensen M, Burisch J, et al
    Autoimmune liver diseases and diabetes.
    Eur J Gastroenterol Hepatol. 2023;35:938-947.
    PubMed     Abstract available


    August 2023
  7. NING H, Li K, Peng Z, Jin H, et al
    The efficacy and safety of pegylated interferon alpha-2b-based immunotherapy for inactive hepatitis B surface antigen carriers.
    Eur J Gastroenterol Hepatol. 2023 Aug 14. doi: 10.1097/MEG.0000000000002627.
    PubMed     Abstract available


  8. ZHOU X, Chen X, Du H, Ye Y, et al
    Antithrombin III activity is associated with prognosis, infection, and inflammation in patients with hepatitis B virus-related acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2023;35:914-920.
    PubMed     Abstract available


  9. CLOONAN DJ, Broekhuis JM, Coe TM, Criss S, et al
    Preferred language and disease severity predict evaluation for liver transplantation among patients admitted with alcohol-associated hepatitis.
    Eur J Gastroenterol Hepatol. 2023;35:907-913.
    PubMed     Abstract available


  10. WANG X, Wei S, Wei Y, Wang X, et al
    The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
    Eur J Gastroenterol Hepatol. 2023;35:889-898.
    PubMed     Abstract available


    July 2023
  11. PEMMASANI G, Tremaine WJ, Suresh Kumar VC, Aswath G, et al
    Sex differences in clinical characteristics and outcomes associated with alcoholic hepatitis.
    Eur J Gastroenterol Hepatol. 2023 Jul 11. doi: 10.1097/MEG.0000000000002612.
    PubMed     Abstract available


  12. MOHAMED R, Yip C, Singh S
    Understanding the knowledge, awareness, and attitudes of the public towards liver diseases in Malaysia.
    Eur J Gastroenterol Hepatol. 2023;35:742-752.
    PubMed     Abstract available


    June 2023
  13. ZHANG Y, Gu Y, Yin S, Wang J, et al
    Baseline albumin-bilirubin score: a predictor for HBeAg clearance in patients with chronic hepatitis B after nucleos(t)ide analogue treatment.
    Eur J Gastroenterol Hepatol. 2023 Jun 22. doi: 10.1097/MEG.0000000000002598.
    PubMed     Abstract available


  14. HITAWALA AA, Almomani A, Onwuzo S, Boustany A, et al
    Prevalence of autoimmune, cholestatic and nonalcoholic fatty liver disease in celiac disease.
    Eur J Gastroenterol Hepatol. 2023 Jun 22. doi: 10.1097/MEG.0000000000002599.
    PubMed     Abstract available


  15. CLOONAN DJ, Broekhuis JM, Coe TM, Criss S, et al
    Preferred language and disease severity predict evaluation for liver transplantation among patients admitted with alcohol-associated hepatitis.
    Eur J Gastroenterol Hepatol. 2023 Jun 6. doi: 10.1097/MEG.0000000000002576.
    PubMed     Abstract available


  16. WANG X, Wei S, Wei Y, Wang X, et al
    The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study.
    Eur J Gastroenterol Hepatol. 2023 Jun 6. doi: 10.1097/MEG.0000000000002583.
    PubMed     Abstract available


    March 2023
  17. COELHO M, Fernandes F, Cardoso SW, Piedade J, et al
    Accuracy and concordance of two-dimensional shear-wave elastography using transient elastography as the reference in chronic viral hepatitis and HIV infection in Rio de Janeiro, Brazil.
    Eur J Gastroenterol Hepatol. 2023 Mar 20. doi: 10.1097/MEG.0000000000002537.
    PubMed     Abstract available


  18. EBIK B, Cangul MS, Yalcin K
    What does quantitative HBsAg level mean in chronic hepatitis D infection?
    Eur J Gastroenterol Hepatol. 2023;35:320-326.
    PubMed     Abstract available


  19. ZHANG P, Liu Z, Fan H, Shi T, et al
    Positive hepatitis B core antibody is associated with advanced fibrosis and mortality in nonalcoholic fatty liver disease.
    Eur J Gastroenterol Hepatol. 2023;35:294-301.
    PubMed     Abstract available


    February 2023
  20. IDENO N, Nozaki A, Chuma M, Ogushi K, et al
    Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2023;35:219-226.
    PubMed     Abstract available


  21. FENG Y, Yao N, Shi L, Zhu Y, et al
    Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment.
    Eur J Gastroenterol Hepatol. 2023;35:212-218.
    PubMed     Abstract available


    January 2023
  22. ZHANG J, Zeng Q, Zhang P, Chen Y, et al
    Efficacy evaluation and prognostic risk factors analysis of precise hepatectomy in the treatment of intermediate and advanced hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2023;35:120-126.
    PubMed     Abstract available


    December 2022
  23. LEE J, Chang JI, Jin YJ, Lee JH, et al
    Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection.
    Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002504.
    PubMed     Abstract available


  24. LEE DU, Ponder R, Lee KJ, Yoo A, et al
    The nationwide trends in hospital admissions, deaths, and costs related to hepatitis C stratified by psychiatric disorders and substance use: an analysis of US hospitals between 2016 and 2019.
    Eur J Gastroenterol Hepatol. 2022 Dec 23. doi: 10.1097/MEG.0000000000002498.
    PubMed     Abstract available


    October 2022
  25. YIBIRIN M, Hosry J, Yepez Guevara E, Granwehr BP, et al
    High sustained virologic response rate after 8 weeks of direct-acting antivirals in cancer patients with chronic hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2022;34:1098-1101.
    PubMed     Abstract available


    September 2022
  26. GARRIDO I, Liberal R, Peixoto A, Macedo G, et al
    "Long-term follow-up and prognosis of celiac hepatitis".
    Eur J Gastroenterol Hepatol. 2022 Sep 23. pii: 00042737-990000000-00077.
    PubMed     Abstract available


    July 2022
  27. HUNYADY P, Herrmann E, Bojunga J, Friedrich-Rust M, et al
    Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury.
    Eur J Gastroenterol Hepatol. 2022;34:801-806.
    PubMed     Abstract available


  28. PARIENTE A, Rosa I, Dharancy S, Hanslik B, et al
    Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study).
    Eur J Gastroenterol Hepatol. 2022;34:791-800.
    PubMed     Abstract available


    May 2022
  29. SUN J, Yu X, Weng Z, Jin L, et al
    The impact of hepatotoxic drugs on the outcome of patients with acute deterioration of hepatitis B virus-related chronic disease.
    Eur J Gastroenterol Hepatol. 2022 May 5. pii: 00042737-990000000-00024.
    PubMed     Abstract available


  30. DOFFOEL M, Tripon S, Ernwein F, Chaffraix F, et al
    Changes in the profile and therapeutic care of people who use drugs with HCV mono-infection: a retrospective study between 2015 and 2019 from a monocentric tertiary referent center in France.
    Eur J Gastroenterol Hepatol. 2022;34:560-566.
    PubMed     Abstract available


    April 2022
  31. ALLGEIER J, Weber S, Todorova R, Neumann J, et al
    Acute liver injury following methylprednisolone pulse therapy: 13 cases from a prospectively collected cohort.
    Eur J Gastroenterol Hepatol. 2022;34:457-461.
    PubMed     Abstract available


    March 2022
  32. TAHTASAKAL CA, Oncul A, Sevgi DY, Demirbas D, et al
    Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment: APRI, FIB-4, King score and GUCI.
    Eur J Gastroenterol Hepatol. 2022;34:308-315.
    PubMed     Abstract available


    February 2022
  33. TOYODA H, Yasuda S, Shiota S, Kumada T, et al
    Adherence to regular surveillance visits for hepatocellular carcinoma in patients with chronic hepatitis C virus infection who achieved sustained virologic response.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97088.
    PubMed     Abstract available


  34. HUANG X, Wang H, Zhang W, Gu E, et al
    Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment.
    Eur J Gastroenterol Hepatol. 2022 Feb 14. pii: 00042737-900000000-97084.
    PubMed     Abstract available


    December 2021
  35. DOFFOEL M, Ernwein F, Chaffraix F, Haumesser L, et al
    Characteristics and care of chronic hepatitis C treated with direct-acting antivirals in migrants.
    Eur J Gastroenterol Hepatol. 2021 Dec 30. pii: 00042737-900000000-97102.
    PubMed     Abstract available


  36. NG A
    Underdiagnosis of hepatitis C in the community: do not forget vulnerable populations.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  37. NG A
    Hepatocellular carcinoma recurrence after directly-acting antiviral therapy: caution with hepatitis C.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  38. BASSO M, Zago D, Pozzetto I, Parisi SG, et al
    Hepatitis C virus viral load distribution in the era of extended access to direct acting antivirals treatment: a real-life single center study.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed    


  39. KUMADA T, Toyoda H, Yasuda S, Ito T, et al
    Impact of switching to tenofovir alafenamide fumarate in patients with entecavir-treated chronic hepatitis B.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


  40. HUBBARD A, Hirode G, Chitnis A, Wong R, et al
    Prevalence of hepatitis B surface antigen and hepatitis B core antibody among adults with latent tuberculosis infection.
    Eur J Gastroenterol Hepatol. 2021;33.
    PubMed     Abstract available


    September 2021
  41. EL KASSAS M, Abdeen N, Omran D, Alboraie M, et al
    Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Sep 21. pii: 00042737-900000000-97142.
    PubMed     Abstract available


  42. PATACCINI G, Pedrozo W, Mathet VL, Biglione MM, et al
    Prevalence of hepatitis D virus in blood donors with different hepatitis B virus markers of infection.
    Eur J Gastroenterol Hepatol. 2021;33:1229.
    PubMed    


  43. PI B, Wang J, Tong Y, Yang Q, et al
    Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.
    Eur J Gastroenterol Hepatol. 2021 Sep 1. pii: 00042737-900000000-97150.
    PubMed     Abstract available


    July 2021
  44. ALEM SA, Eletreby R, Abdellatif Z, Ramadan A, et al
    Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jul 6. pii: 00042737-900000000-97183.
    PubMed     Abstract available


  45. EL RAY A, Fouad R, ElMakhzangy H, El Beshlawy M, et al
    Characterizing a cohort of Egyptian patients with acute-on-chronic liver failure.
    Eur J Gastroenterol Hepatol. 2021;33:1023-1028.
    PubMed     Abstract available


    June 2021
  46. LIU X, Zhang J, Wei X, Duan Z, et al
    HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 Jun 29. pii: 00042737-900000000-97185.
    PubMed     Abstract available


  47. KHAN A, Sami K, Malik A, Mujtaba Bhinder M, et al
    Clinical outcomes and healthcare utilization of acute hepatitis A virus infection with acute kidney injury in hospitalized patients.
    Eur J Gastroenterol Hepatol. 2021 Jun 17. pii: 00042737-900000000-97190.
    PubMed     Abstract available


    May 2021
  48. KOSEKLI MA
    Mean platelet volume and platelet to lymphocyte count ratio are associated with hepatitis B-related liver fibrosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97205.
    PubMed     Abstract available


  49. SHI K, Li P, Xue D, Liu Y, et al
    Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis.
    Eur J Gastroenterol Hepatol. 2021 May 31. pii: 00042737-900000000-97202.
    PubMed     Abstract available


    April 2021
  50. HAYES KN, Burkard T, Weiler S, Tadrous M, et al
    Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
    Eur J Gastroenterol Hepatol. 2021 Apr 21. pii: 00042737-900000000-97232.
    PubMed     Abstract available


  51. EKMEN N, Can G, Can H
    Preliminary examination of the relations between disease stage, illness perceptions, coping strategies, and psychological morbidity in chronic hepatitis B and C guided by the Common-Sense Model of Illness.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97249.
    PubMed     Abstract available


  52. YEO YH, Kam LY, Le MH, Jeong D, et al
    A population-based US study of hepatitis C diagnosis rate.
    Eur J Gastroenterol Hepatol. 2021 Apr 16. pii: 00042737-900000000-97245.
    PubMed     Abstract available


  53. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Usefulness of serial FIB-4 score measurement for predicting the risk of hepatocarcinogenesis after hepatitis C virus eradication.
    Eur J Gastroenterol Hepatol. 2021 Apr 9. pii: 00042737-900000000-97256.
    PubMed     Abstract available


    January 2021
  54. EL KASSAS M, Alboraie M, El-Sayed M, Elbehiry S, et al
    Effect of disease stage and treatment outcomes on the dynamics of liver functions during and after treatment of hepatitis C with directly acting antivirals.
    Eur J Gastroenterol Hepatol. 2021 Jan 14. doi: 10.1097/MEG.0000000000002043.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.